Open an account

Ceribell

CBLL · NASDAQ

$27.68+$1.68 (+6.46%)TodayMarket closed ·
Prev close $26.00

About CBLL

Ceribell, Inc. is a commercial-stage medical technology company, which engages in the provision of transforming the diagnosis and management of patients with serious neurological conditions. The company is headquartered in Sunnyvale, California and currently employs 327 full-time employees. The company went IPO on 2024-10-11. The firm has developed the Ceribell System, a point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining highly portable and rapidly deployable hardware with artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared (510(k)) for indicating suspected seizure activity and utilized in intensive care units and emergency rooms across the United States. Clarity, its machine learning algorithm, continuously interprets a patient’s EEG waveforms and displays actionable insights regarding seizure activity on the recorder. Its EEG portal is a cloud-based portal that enables real-time remote access to a patient’s EEG data.

Employees
327
Headquarters
Sunnyvale, California
Listed
Oct 11, 2024
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
ceribell.com

CBLL key statistics

Market cap
1.06B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
409.74K
Volume
593.28K
Open price
$26.00
High today
$27.91
Low today
$26.00
52 Week high
$27.94
52 Week low
$10.85

Ceribell (CBLL) at a glance

Ceribell (CBLL) last traded at $27.68, with a market cap of 1.06B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $26.00 and $27.91. The current price is 6.5% above the day's low and 0.8% below its high.

Volume so far is 593.28K shares, above the average of 409.74K shares a day.

Over the past year Ceribell has ranged from $10.85 to $27.94, and now sits 98% of the way up that range.

Ceribell met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.51 per share against an estimate of -$0.4807.

The average analyst price target is $28.56, 3.2% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 9 analystsAvg $28.56
Low
$24.24
Now
$27.68
High
$33.60

CBLL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 12.1% on average.

  1. Q3 FY24: reported -$1.85 per share against an estimate of -$0.3494
  2. Q4 FY24: reported -$0.40 per share against an estimate of -$0.3244
  3. Q1 FY25: reported -$0.36 per share against an estimate of -$0.4318
  4. Q2 FY25: reported -$0.38 per share against an estimate of -$0.4006
  5. Q3 FY25: reported -$0.37 per share against an estimate of -$0.4218
  6. Q4 FY25: reported -$0.36 per share against an estimate of -$0.4206
  7. Q1 FY26: reported -$0.52 per share against an estimate of -$0.3978
  8. Q2 FY26: reported -$0.51 per share against an estimate of -$0.4807

CBLL news

  • CeriBell's Earnings: A Preview

  • Forecasting The Future: 5 Analyst Projections For CeriBell

  • Press releaseGlobe Newswire

    AI Diagnostics: The End of the High-Cost Imaging Era

  • Press releasePRNewswire

    AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs

  • Press releaseGlobe Newswire

    Global AI Infrastructure Shift Ignites Biotech Growth Phase

  • Earnings Scheduled For August 5, 2025

  • Press releasePRNewswire

    AI Tools That Talk, Scan, and Save Lives Are Reshaping the Investment Landscape

  • Earnings Scheduled For May 8, 2025

Similar companies

Companies in the same industry as Ceribell

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.